The expansion significantly boosts cell therapy capabilities and serves as a complementary addition to suspension and adhesion viral vector services at the US Cell and Gene Site
AGC Biologics adds three new Grade B cell therapy suites to its Longmont facility. (Credit: AGC Biologics)
AGC Biologics, a biopharmaceutical contract development and manufacturing organisation (CDMO), has announced a substantial expansion in its capabilities with the introduction of three new Grade B cell therapy suites to its Longmont, Colorado facility.
This enhancement at AGC Biologics Longmont encompasses two new Process Suites and one additional Flex suite, significantly augmenting the facility’s capacities. Spanning over 30,000ft2, these new, separate multiproduct suites are characterised by cutting-edge modular clean room design, adaptable capacity configurations, and the latest cell therapy equipment for both open and closed processes. This expanded infrastructure caters to the manufacturing of both autologous and allogeneic cell therapies.
With the integration of these three new cell therapy suites, AGC Biologics’ Longmont site further bolsters its role as a pivotal North American hub for cell and gene therapy services. The facility now offers comprehensive cell therapy development and manufacturing services all under one roof. This expansion complements the existing robust viral vector development and manufacturing services provided by the site. This consolidation benefits developers by providing a centralised location that covers a full spectrum of services, aiding in bringing products to market.
The Longmont campus boasts additional noteworthy features such as early-stage process development services, commercial manufacturing, quality control and analytics, fill-finish capabilities, and an onsite warehouse. The spaciousness of the campus allows AGC Biologics to potentially add nine more cell therapy suites to meet growing market demands.
AGC Biologics Colorado general manager Whitney Sandberg said: “The new cell therapy suites are a tremendous achievement for this site. We have integrated the latest technology to complete our unique cell therapy services and have created ideal environments for developing these life-changing treatments.”
“This is the final piece for this campus that accompanies our comprehensive viral vector capabilities and gives developers a true end-to-end manufacturing site in North America to support their product’s every need, at any stage.”
AGC Biologics successfully acquired the Longmont campus in August 2021. The scientists at this facility boast an impressive history of over 20 years of expertise in handling intricate cell therapy and viral vector products and materials. This experience underscores the facility’s ability to manage complex biopharmaceutical processes effectively.